Helping you make wiser investment decisions

Pharmaceuticals, health and wellness

GlaxoSmithKline, under activist pressure, gets some relief as Elliott won’t push for sale or slash R&D: report

Investors have been eyeing a potential shakeup at GlaxoSmithKline ever since Elliott Management took a large stake in the company last month. After concerns of a potential sale emerged last week, it appears the activist investor aims to take a more conservative tack. Elliott won’t angle to sell off GlaxoSmithKline’s pharmaceuticals and vaccines business, nor does it plan to […]

Eli Lilly hit with DOJ subpoena over New Jersey factory making COVID-19 drug

Earlier this month, Eli Lilly’s COVID-19 drug factory in New Jersey garnered unwanted headlines for quality control snafus and alleged document tampering. Now, the Department of Justice has stepped in to investigate.  On Thursday, Lilly revealed that the Department of Justice has issued a subpoena demanding documents relating to the site in Branchburg, New Jersey. The site produces doses of Lilly’s […]

Pandemic relief: Pharma sales rep salaries—and job satisfaction—actually increased in 2020

It turns out pharma sales reps didn’t need to worry about a pandemic effect on their salaries. Pharma reps’ average pay jumped to $158,013 in 2020 from $151,217 the previous year, according to MedReps’ annual survey. That’s good news for the three-fourths of reps who last March said they were concerned about pay cuts. What […]

Myovant and Pfizer’s uterine fibroids med scores FDA nod, setting up showdown with AbbVie

Fresh off the back of Myovant Sciences’ first FDA win for relugolix in prostate cancer late last year, the Swiss pharma can now add a second indication to its flagship drug’s resume.  The U.S. FDA on Wednesday approved Myovant’s relugolix in combination with two hormone drugs as the first once-daily treatment for heavy menstrual bleeding linked to […]

AbbVie, building out its post-Humira future, posts 5 late-stage trial wins for Skyrizi and Rinvoq

As AbbVie comes under renewed scrutiny for its pricing and patenting strategies, the company is still working to build out the case for its next-gen immunology drugs Skyrizi and Rinvoq. In Crohn’s disease, Skyrizi beat placebo in two separate phase 3 studies examining different dosages in adults with moderate to severe disease who have had various prior treatments. The […]

Xtandi raise, Padcev lift and a women’s health surprise: Astellas outlines $17B 5-year plan

Astellas has been enjoying solid performance lately thanks to a couple of cancer drugs. Now, the Japanese pharma has unveiled its five-year goals in an upbeat plan that one analyst figures “looks realistic.” By March 2026, Astellas expects its sales to jump to around JPY 1.8 trillion ($16.5 billion), from JPY 1.25 trillion in the […]

Vectura, after reinventing itself as a CDMO, accepts $1.4B buyout offer from Carlyle

A few short years after rebranding itself as a CDMO, inhalation specialist Vectura’s pivot has paid off big time—courtesy of prominent healthcare investment firm The Carlyle Group.  Vectura has agreed to a buyout by Carlyle for £958 million ($1.36 billion)—a 32% premium on the company’s closing market value Tuesday. Vectura shareholders are in line to receive £1.55 ($2.19) […]

Impel NeuroPharma migraine campaign uses map artwork to spotlight mind-gut connection for many sufferers

Migraines are difficult to navigate, with patients often mapping their own routes to try to avoid the debilitating episodes and to deal with them when they arise. Impel NeuroPharma’s new campaign brings that idea to life with custom topography created by a well-known artist—and migraine sufferer himself—to show the complexity of the condition and draw attention […]

Otsuka creates Gen J in new Jynarque ads that aim to separate kidney from disease

Otsuka wants to create a next generation of kidney disease patients—Gen J. Short for Generation J, with the J standing for Jynarque, they’re the first age group who may be able to control progression of a rare kidney disease. Autosomal dominant polycystic kidney disease, or ADPKD, is an inherited disease, and many younger people have […]

BioCryst’s persistence for patient insights leads to a bigger market for HAE drug Orladeyo

Sometimes finding out how patients really feel about treatment takes persistence. That’s what BioCryst Pharmaceuticals learned when it started talking to patients about its new oral preventative treatment for hereditary angioedema. Two years ago, after pivotal trial results came in for the drug that would become Orladeyo, BioCryst had just begun its market research with a study […]

Apellis’ PNH victory lap: Newly FDA-approved Empaveli helped patients without prior Soliris treatment

Apellis Pharmaceuticals is taking a victory lap. Less than two weeks after the FDA approved Apellis’ C3 inhibitor pegcetacoplan, marketed as Empaveli, for patients with a rare blood disorder known as paroxysmal nocturnal hemoglobinuria (PNH), the company is touting late-stage data that show its drug can help patients regardless of prior treatment status. The phase 3 trial, […]

Biogen’s $1B Swiss plant scores regulatory nod as drugmaker awaits pivotal FDA decision on aducanumab

Despite a flurry of uncertainty surrounding Biogen’s Alzheimer’s hopeful aducanumab, the company has forged ahead with its launch preparations ahead of a pending FDA decision. Now, its Swiss manufacturing facility is a step closer to eventually churning out doses—should the drug score an approval. Switzerland’s medicines surveillance authority, the Swiss Agency for Therapeutic Products (Swissmedic), issued Biogen’s […]